A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer
EF Smit, E Fokkema, B Biesma, HJM Groen… - … journal of cancer, 1998 - nature.com
The purpose of the study was to delineate the efficacy and toxicity of paclitaxel (Taxol, Bristol
Myers Squibb) in the treatment of drug resistant small-cell lung cancer (SCLC). Patients …
Myers Squibb) in the treatment of drug resistant small-cell lung cancer (SCLC). Patients …
… phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non–small-cell lung cancer
EF Smit, SA Burgers, B Biesma, HJM Smit… - Journal of Clinical …, 2009 - ascopubs.org
Purpose We performed a randomized phase II trial comparing pemetrexed with pemetrexed
plus carboplatin (PC) in patients experiencing relapse after platinum-based chemotherapy. …
plus carboplatin (PC) in patients experiencing relapse after platinum-based chemotherapy. …
Pemetrexed versus erlotinib in pretreated patients with advanced non–small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 …
… benefit over placebo in pretreated patients with advanced NSCLC.10 The improved outcome
with EGFR TKIs is mainly confined to never smokers and patients who have tumors that …
with EGFR TKIs is mainly confined to never smokers and patients who have tumors that …
[HTML][HTML] Pooled analysis of CNS response to alectinib in two studies of pretreated patients with ALK-positive non–small-cell lung cancer
SM Gadgeel, AT Shaw, R Govindan… - Journal of Clinical …, 2016 - ncbi.nlm.nih.gov
… Crizotinib was the first anaplastic lymphoma kinase (ALK) inhibitor to receive US Food
and Drug Administration (FDA) approval for the treatment of advanced ALK-positive non–small-cell …
and Drug Administration (FDA) approval for the treatment of advanced ALK-positive non–small-cell …
Morphologic variations of small cell lung cancer: A histopathologic study of pretreatment and posttreatment specimens in 104 patients
M Sehested, FR Hirsch, K Østerlind, JE Olsen - Cancer, 1986 - Wiley Online Library
… relationship between pretreatment SCCL-large cell mor… three patients with SCCL-large cell
morphology at autopsy could be that postmortem autolysis obscures the features of this tumor …
morphology at autopsy could be that postmortem autolysis obscures the features of this tumor …
[HTML][HTML] Efficacy differences of pemetrexed by histology in pretreated patients with stage IIIB/IV non-small cell lung cancer: review of results from an open-label …
K Kubota, S Niho, S Enatsu, Y Nambu… - Journal of Thoracic …, 2009 - Elsevier
… in patients with advanced non-small cell lung cancer (NSCLC) consistently showed greater
survival benefit of pemetrexed in patients with nonsquamous cell carcinoma … cell carcinoma …
survival benefit of pemetrexed in patients with nonsquamous cell carcinoma … cell carcinoma …
[HTML][HTML] A phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in pretreated patients with small-cell lung cancer
F de Marinis, A Atmaca, M Tiseo, L Giuffreda… - Journal of Thoracic …, 2013 - Elsevier
… -cell lung cancer and SCLC models; this agent was also tested in non–small-cell lung cancer
patients in … Disease stabilization could be considered a clinically relevant result in patients …
patients in … Disease stabilization could be considered a clinically relevant result in patients …
Clinical significance of pretreatment plasma biomarkers in advanced non-small cell lung cancer patients
S Wang, X Han, X Hu, X Wang, L Zhao, L Tang… - Clinica chimica acta, 2014 - Elsevier
Background The use of biomarkers for selecting non-small cell lung cancer (NSCLC) patients
for treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) …
for treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) …
Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR. 26): a double-blind, randomised …
… On this basis, we aimed to assess dacomitinib versus best supportive care in a phase 3
setting of an unselected population of heavily pretreated patients with non-small-cell lung cancer…
setting of an unselected population of heavily pretreated patients with non-small-cell lung cancer…
[HTML][HTML] Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial
… In this study, vandetanib showed moderate efficacy in pretreated patients with advanced …
been reported for small molecular inhibitors in pretreated patients with typical oncogene-driven …
been reported for small molecular inhibitors in pretreated patients with typical oncogene-driven …
相关搜索
- carboplatin in patients cell lung cancer
- markers in patients cell lung cancer
- asian patients cell lung cancer
- japanese patients cell lung cancer
- non-small cell lung cancer pretreated patients
- previously treated patients cell lung cancer
- cell lung cancer patients clinical significance
- histologic changes cell lung carcinoma
- first line dacomitinib cell lung cancer